SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
Frequently asked questions
What sector does Sk Biopharmaceuticals Co Ltd (326030) operate in?
Sk Biopharmaceuticals Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Sk Biopharmaceuticals Co Ltd (326030) current stock price?
As of the latest data, Sk Biopharmaceuticals Co Ltd stock price is ₩87,600, with a previous close of ₩88,200. Sk Biopharmaceuticals Co Ltd lost -₩600 in the last trading session, representing a -0.68% loss.
What is Sk Biopharmaceuticals Co Ltd (326030) current market capitalization?
Sk Biopharmaceuticals Co Ltd market cap is approximately 6.86 trillion.
Does Sk Biopharmaceuticals Co Ltd (326030) pay dividends?
No. Sk Biopharmaceuticals Co Ltd does not pay a dividend.
How did Sk Biopharmaceuticals Co Ltd (326030) perform in its most recent earnings report?
In the last report (March 31, 2026), Sk Biopharmaceuticals Co Ltd posted an EPS surprise of 179.2% and a revenue surprise of 5.8%.
When is Sk Biopharmaceuticals Co Ltd (326030) next earnings report?
Sk Biopharmaceuticals Co Ltd is expected to release its next earnings report on June 30, 2026.
What is Sk Biopharmaceuticals Co Ltd (326030) beta (volatility) score?
Sk Biopharmaceuticals Co Ltd has a beta of 0.728, indicating lower volatility than the overall market.
